Sciele Pharma Will Market Clonicel Under Addrenex Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Addrenex will submit NDA for sustained-release clonidine for hypertension later this year, followed by application for ADHD.
You may also be interested in...
Sciele And Addrenex Seek Hypertension Approval For Sustained-Release Clonidine
The 12-hour formulation is designed to improve clonidine’s side effect profile.
Sciele And Addrenex Seek Hypertension Approval For Sustained-Release Clonidine
The 12-hour formulation is designed to improve clonidine’s side effect profile.
Sciele/LifeCycle’s “Meltdose” Fenofibrate Clears FDA
Sciele will launch fenofibrate formulation in 40 mg and 120 mg strengths for hyperlipidemia and hypertriglyceridemia by the end of 2007.